Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929695 · ClinicalTrials.gov registry record · Phase 3
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 164
- Enrollment target
NCT00929695 is a Phase 3 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 164 participants.
The verdict
NCT00929695, a Phase 3 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 164 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying low-dose prednisone or methylprednisolone to see how well they work compared with standard-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute graft-versus-host disease (GVHD). Glucocorticoids, such as prednisone or methylprednisolone at a starting dose of 2 mg/kg/day are standard treatment for acute graft-versus-host disease caused by a donor stem cell transplant. It is not yet known whether low-dose glucocorticoids are more effective than standard-dose glucocorticoids in treating acute graft-versus-host-disease
Interventions
- DRUG prednisone
- OTHER questionnaire administration
- DRUG methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929695
The ClinicalTrials.gov registry entry for NCT00929695 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00929695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929695 about?
NCT00929695 is a clinical study titled "Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease". This randomized phase III trial is studying low-dose prednisone or methylprednisolone to see how well they work compared with standard-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute graft-versus-host disease (GVHD). Glucocorticoids, such as prednisone or methyl...
What is the current status of trial NCT00929695?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 164 participants. The study started on 2009-06. Estimated completion is 2015-12-14.
What interventions are being tested in trial NCT00929695?
The interventions under investigation include: prednisone (DRUG), questionnaire administration (OTHER), methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT00929695?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.